Comparison Of The Clinical Efficacy Of Concurrent Chemoradiotherapy With Or Without Adjuvant Chemotherapy Versus Intensity-Modulated Radiotherapy Alone For Treating Stage Ⅱ Nasopharyngeal Carcinoma

Objective This study aimed to explore whether concurrent chemoradiotherapy (CCRT) with or without Adjuvant Chemotherapy (AC) could improved the survival in stage II nasopharyngeal carcinoma (NPC).Methods Patients with stage II NPC treated with CCRT (n=80) or CCRT+AC (n=40) or IMRT alone (n=42) between January 2007 and September 2014 were retrospectively analyzed. The three patient groups were matched based on prognostic factors. All patients were treated with IMRT. The endpoint was overall survival (OS), distant metastasis-free survival (DMFS), locoregional relapse-free survival (LRRFS), and failure-free survival (FFS). The treatment-related acute toxicity reactions between the three groups were compared also.Results The three groups indicated similar outcomes:survival of the CCRT group, CCRT+AC group and RT alone group were (93.9%,95.0%,95.2%, P=0.937) for OS, (96.8%,94.9%,93.0%, P=0.756) for LRRFS, (91.1%,97.5%, 100%, P=0.185) for DMFS and (84.9%,92.5%,93.0%, P=0.597) for FFS. Univariate analysis indicated that older age predicted lower LRRFS and FFS. The CCRT and CCRT+AC groups showed more acute toxicity reactions, especially in bone marrow suppression, Liver dysfunction, gastrointestinal reactions (nausea/vomiting) and weight loss.Conclusion CCRT with or without AC did not appear to improve the prognosis of patients with stage Ⅱ NPC over IMRT alone, but increased the treatment-related acute toxicity reactions.